EUR 0.02
(-3.52%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 10.34 Million EUR | -94.88% |
2022 | 2.99 Million EUR | -30.71% |
2021 | 4.32 Million EUR | 154.53% |
2020 | 1.69 Million EUR | -79.33% |
2019 | 8.21 Million EUR | -22.45% |
2018 | 10.59 Million EUR | -44.25% |
2017 | 18.99 Million EUR | 551.19% |
2016 | 2.91 Million EUR | 98.02% |
2015 | 1.47 Million EUR | -27.42% |
2014 | 2.02 Million EUR | -72.49% |
2013 | 7.37 Million EUR | -7.53% |
2012 | 7.98 Million EUR | 274.08% |
2011 | 2.13 Million EUR | -18.97% |
2010 | 2.63 Million EUR | 38.65% |
2009 | 1.89 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 592.92 Thousand EUR | 0.0% |
2023 Q2 | 68.43 Thousand EUR | 0.0% |
2023 FY | 153.19 Thousand EUR | -94.88% |
2023 Q4 | 7.21 Million EUR | 0.0% |
2022 Q2 | 83.25 Thousand EUR | 0.0% |
2022 Q4 | 2.35 Million EUR | 0.0% |
2022 FY | 2.99 Million EUR | -30.71% |
2021 FY | 4.32 Million EUR | 154.53% |
2021 Q2 | 1.67 Million EUR | 0.0% |
2021 Q4 | 6.45 Million EUR | 0.0% |
2020 Q2 | 5.63 Million EUR | 0.0% |
2020 Q4 | 636.93 Thousand EUR | 0.0% |
2020 FY | 1.69 Million EUR | -79.33% |
2019 Q2 | 4.67 Million EUR | 0.0% |
2019 Q4 | 3.53 Million EUR | 0.0% |
2019 FY | 8.21 Million EUR | -22.45% |
2018 FY | 10.59 Million EUR | -44.25% |
2018 Q4 | 5.43 Million EUR | 0.0% |
2018 Q2 | 5.16 Million EUR | 0.0% |
2017 Q2 | 10.67 Million EUR | 0.0% |
2017 FY | 18.99 Million EUR | 551.19% |
2017 Q4 | 8.32 Million EUR | 0.0% |
2016 Q2 | 1.61 Million EUR | 0.0% |
2016 FY | 2.91 Million EUR | 98.02% |
2016 Q4 | 1.3 Million EUR | 0.0% |
2015 FY | 1.47 Million EUR | -27.42% |
2015 Q4 | 3.14 Million EUR | 0.0% |
2015 Q2 | 1.66 Million EUR | 0.0% |
2014 Q2 | 851.73 Thousand EUR | 0.0% |
2014 Q4 | 1.17 Million EUR | 0.0% |
2014 FY | 2.02 Million EUR | -72.49% |
2013 Q2 | 1.38 Million EUR | 7684.74% |
2013 Q1 | 17.84 Thousand EUR | 0.0% |
2013 FY | 7.37 Million EUR | -7.53% |
2013 Q4 | 1.26 Million EUR | 7010.45% |
2013 Q3 | 17.84 Thousand EUR | -98.72% |
2012 Q1 | 19.22 Thousand EUR | 0.0% |
2012 Q4 | 17.84 Thousand EUR | -7.18% |
2012 Q3 | 19.22 Thousand EUR | 0.0% |
2012 FY | 7.98 Million EUR | 274.08% |
2012 Q2 | 19.22 Thousand EUR | 0.0% |
2011 Q2 | 17.34 Thousand EUR | 0.0% |
2011 Q3 | 17.34 Thousand EUR | 0.0% |
2011 Q4 | 19.22 Thousand EUR | 10.89% |
2011 FY | 2.13 Million EUR | -18.97% |
2011 Q1 | 17.34 Thousand EUR | 0.0% |
2010 Q2 | 17.77 Thousand EUR | 0.0% |
2010 Q3 | 17.77 Thousand EUR | 0.0% |
2010 Q4 | 17.34 Thousand EUR | -2.45% |
2010 Q1 | 17.77 Thousand EUR | 0.0% |
2010 FY | 2.63 Million EUR | 38.65% |
2009 Q3 | 49.9 Thousand EUR | 0.0% |
2009 Q1 | 49.9 Thousand EUR | 0.0% |
2009 FY | 1.89 Million EUR | 0.0% |
2009 Q2 | 49.9 Thousand EUR | 0.0% |
2009 Q4 | 17.77 Thousand EUR | -64.38% |
2008 Q4 | 49.9 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -147.631% |
ABIVAX Société Anonyme | 127.37 Million EUR | 91.88% |
Adocia SA | 15.62 Million EUR | 33.818% |
Aelis Farma SA | 18.81 Million EUR | 45.037% |
Biophytis S.A. | 14.33 Million EUR | 27.834% |
Advicenne S.A. | 8.21 Million EUR | -25.91% |
genOway Société anonyme | 16.73 Million EUR | 38.204% |
IntegraGen SA | 5.35 Million EUR | -93.247% |
Medesis Pharma S.A. | 1.56 Million EUR | -561.11% |
NFL Biosciences SA | 4.37 Million EUR | -136.459% |
Plant Advanced Technologies SA | 2.76 Million EUR | -274.109% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -502.081% |
Sensorion SA | 27.05 Million EUR | 61.767% |
Theranexus Société Anonyme | 3 Million EUR | -244.213% |
TME Pharma N.V. | 5.49 Million EUR | -88.167% |
Valbiotis SA | 9.86 Million EUR | -4.808% |
TheraVet SA | 1.64 Million EUR | -529.05% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 49.097% |
DBV Technologies S.A. | 89.4 Million EUR | 88.431% |
Genfit S.A. | 54.8 Million EUR | 81.126% |
GeNeuro SA | 14.35 Million EUR | 27.956% |
Innate Pharma S.A. | 64.57 Million EUR | 83.981% |
Inventiva S.A. | 120.18 Million EUR | 91.394% |
MaaT Pharma SA | 21.59 Million EUR | 52.109% |
MedinCell S.A. | 32.92 Million EUR | 68.582% |
Nanobiotix S.A. | 58.92 Million EUR | 82.447% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 56.151% |
Poxel S.A. | 28.76 Million EUR | 64.041% |
GenSight Biologics S.A. | 32.66 Million EUR | 68.33% |
Transgene SA | 31.23 Million EUR | 66.881% |
Valneva SE | 134.92 Million EUR | 92.334% |